The purpose of this research study is to prepare exametazime (d,l-HMPAO) kit for labeling with 99m-technetium radionuclide as a brain perfusion diagnostic system. Firstly, the active pharmaceutical ingredient d,l-HMPAO was prepared in two steps with the purity of 99.29 %. Its molecular structure was characterized using elemental analysis, Fourier-transform infrared spectroscopy (FT-IR), and nuclear magnetic resonance (NMR) technique. In second step, the d,l-HMPAO kit was prepared using six different formulations and labeled by technetium-99m radionuclide. The high radiochemical yield was attributed to the high amount of SnCl2 and adding phosphate buffer. The animal studies were conducted on the three-month old male Wistar rats. The results of the biodistribution studies revealed that, the mean activity in brain of all rats was above 1% ID/g. This showed the high isomerism purity of the synthesized compound (d,l-HMPAO) and optimization of the suggested formulations.
Introduction
Exametazime which is mainly known by its chemical name hexamethylpropyleneamine-oxime or HMPAO has been used as a chelating agent to bind with technetium-99m [1] . Technetium-99m ( 99m Tc) is an isotope of technetium-99 and a gamma-emitter agent utilized in various fields of diagnostic medicine. In addition, based on its favorable qualities, 99mTc is one of the most investigated radioisotopes in nuclear research areas [2] . The HMPAO ligand comprises of two diastereomeric isoforms are including d,l-HMPAO and meso-HMPAO [3] . 99m Tc-d,l-HMPAO is a well-established radiotracer in cerebral imaging and leukocytes labeling for detection of several infectious and inflammatory diseases [4, 5] . 99m Tc-d,l-HMPAO is the first 99mTc-labeled tracer used for evaluating the regional cerebral blood (rCBF) [6] [7] [8] [9] [10] .
Regional cerebral blood flow represents the amount of blow flow to a specific region of the brain in a predetermined time [11] . Considering the fact that various pathological processes in the brain originate from alterations in cerebral blood perfusion, the diagnostic capabilities of 99m Tc-d,l-HMPAO is of particular importance in early detection of neurocognitive disorders such as schizophrenia [12] , major depressive disorder [13] , epilepsy [14] , migraine [15] , meningioma [16] , and Alzheimer's [17] . 99m Tc-d,l-HMPAO SPECT (single-photon emission computed tomography) is considered to be one of the most reliable scintographic studies and imaging methods in early diagnosis of dementia [18] . Due to its lipophilic nature, 99mTc-d,l-HMPAO readily permeates through blood-brain barrier (BBB) and converts into hydrophilic species incapable of back-diffusion thus guaranteeing entrapment of the agent in brain cells.
Within one minute after the injection of 99mTc-d,l-HMPAO, a maximum of 3.5-7.0% of the injected dose is up-taken into the brain although up to 15% of the activity is lost after about only 2 min [19] [20] [21] . The objective of the current study was to introduce a novel route for the synthesis of the active pharmaceutical ingredient (d,l-HMPAO) for the preparation of 99mTc-d,l-HMPAO radiopharmaceutical.
In addition, different kit formulations were suggested, with minor alterations in previously investigated formulations, and further analyzed to reach two optimum formulations with the best observed results. Due to the inherent instability of 99mTc-d,l-HMPAO and its spontaneously degradation into hydrophilic agents, quality control measures were carried out in a span of 5 to 30 min after labeling procedure.
Furthermore, to gain a better insight into this radiopharmaceutical's behavior and function in vivo, animal studies were conducted and regional brain perfusion was investigated in Wistar rats. Moreover, the amounts of liver and kidney uptake were measured as indicators of metabolism and elimination, respectively. analyzed with Lura image analysis software. 
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Evaluation of d,l-HMPAO Kit Formulation
As seen in Table 1 min biodistribution results are presented in Table 1 . As presented in Table 1 , the mean activity in brain of all rats reached above 1% ID/g, indicating complete purity of synthesized isomer and optimization of the suggested formulations. Moreover, the high mean counts in liver suggests hepatic metabolism of the investigated agent.
Results and Discussion
Characterization of d,l-HMPAO
The purity of the d,l-HMPAO was gained by HPLC using a μ-Porasil normal phase column, with a UV 210 nm detector, with methanol:0.4M NH4OH (95:5) as the mobile phase at a flow rate of 1 mL/min. In this system, there is a difference of 1 min between the retention times of the d,l-HMPAO and the meso-HMPAO. The HPLC analysis showed % 99.29 for this isomer (d,l-HMPAO).
Melting point of d,l-HMPAO isomer: 133 o C. 
Results of the d,l-HMPAO Kit Formulations
Previously a reported formulation kit of HMPAO was as a Unexpectedly, results (comparison between formulation E and F) revealed that, radiochemical yield was same at different formulations.
Conclusions
This work aimed at preparation of d,l-HMPAO kit for labeling with 99m-technetium radionuclide as a brain was found that, the mean activity in brain of all rats was above 1% ID/g. This indicated complete purity of the synthesized isomer (d,l-HMPAO) and optimization of the suggested formulations.
